Skip to content

EBITDA at other companies

AMP
Amphastar PharmaceuticalsAMPH
$27.98M-45.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$30.2M+63.9%
PTH
Pelthos Therapeutics Inc.PTHS
-$11.59M-532%
XOMA Corporation logo
XOMA CorporationXOMA
$412K-93.6%
Baxter International logo
Baxter InternationalBAX
Royalty Pharma logo
Royalty PharmaRPRX

Other financials

Income statement

See full
Revenue--100%
Gross profit-$1.9M-52.7%
Operating income-$3.9M-35.4%
Net income-$2.6M+1.4%
EPS (diluted)-$0.10+37.5%

Balance sheet

See full
Cash & equivalents$3.8M-29.0%
Total debt$3.4M-79.7%
Total equity$18.5M+230%
Total assets$30.2M+101%

Cash flow

See full
Operating cash flow-$3.4M+2.0%
CapEx-
Free cash flow-$2.3M+42.9%

Valuation

See full
Market cap$53.46M+516%
P/S53,456.6×+53,135×

Profitability

See full
Gross margin-127.7%-136pp
Operating margin-1,451,600%-1,507,145pp
Net margin-1,425,300%-1,471,200pp
FCF margin-5,116.7%-6,779pp

Returns & leverage

See full
Return on equity-118.4%+15.4pp
Debt / equity0.2×
Current ratio5.3×+2.2×

Where this comes from

Calculated from Talphera, Inc.’s reported figures.

$3.0Mebit+
-Depreciation Depletion & Amortization
=-$3M

The official record: Talphera, Inc.’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Talphera, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Talphera, Inc.'s EBITDA?
Talphera, Inc. (TLPH) reported EBITDA of -$3M in Q4 2024.
What is the long-term trend for Talphera, Inc.'s EBITDA?
Over 2 years (2021 to 2024), Talphera, Inc.'s EBITDA has grown at a -33.0% compound annual growth rate (CAGR), from -$33.99M to -$15.25M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.